Advancing Global Pharmacoequity in Oncology

Area of Science:

• Global Health
• Pharmacoeconomics
• Oncology

Background:

• Cancer drug availability and affordability are critical issues, causing significant survival disparities between high-income and low- and middle-income countries (LMICs).
• Existing strategies for improving access in LMICs, such as charity and differential pricing, have shown limited success.
• There is an urgent need for innovative approaches to reduce cancer medicine prices and enhance access in LMICs to promote global health equity.

Purpose of the Study:

• To identify and discuss strategies for multilateral organizations to reduce cancer drug prices in LMICs.
• To review empirical data and lessons learned from infectious disease medication access programs (HIV, COVID-19).
• To propose actionable solutions for improving cancer medicine accessibility and affordability in LMICs.

Main Methods:

• Analysis of empirical data from medication access programs for HIV and COVID-19.
• Review of lessons learned from international collaboration and policy proposals.
• Discussion of three key strategies: regional manufacturing hubs, compulsory licensing, and drug price transparency.

Main Results:

• Three core strategies are proposed: establishing regional technology transfer and manufacturing hubs, expanding and streamlining the use of compulsory licenses, and implementing global standards for drug price transparency.
• Critiques of these proposed policies are addressed, and their integration with existing disease-centered initiatives is explored.
• The potential impact of these strategies on advancing pharmacoequity and global cancer control is highlighted.

Conclusions:

• International collaboration, modeled after successful HIV and COVID-19 responses, is crucial for advancing cancer drug access in LMICs.
• Implementing strategies for increased accessibility and affordability of cancer medicines is vital for global cancer control.
• Addressing the growing cancer burden in LMICs through improved medication access aligns with achieving the United Nations Sustainable Development Goals.